世界中医药
文章摘要
引用本文:黄颖锋1,孙广信1,周丽娟2,卢春玲1,常双喜1.苏黄止咳胶囊对于慢性阻塞性肺疾病急性加重期患者的临床疗效[J].世界中医药,2017,(09):.  
苏黄止咳胶囊对于慢性阻塞性肺疾病急性加重期患者的临床疗效
Observation and Analysis of Clinical Efficacy of Suhuang Zhike Capsule for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
投稿时间:2017-05-03  
DOI:10.3969/j.issn.1673-7202.2017.09.009
中文关键词:  慢性阻塞性肺疾病  苏黄止咳胶囊  肺功能  免疫功能  生命质量
English Keywords:Chronic obstructive pulmonary disease  Suhuang Zhike capsule  Pulmonary function  Immune function  Quality of life
基金项目:河南省卫生和计划生育委员会项目(201602333)
作者单位
黄颖锋1,孙广信1,周丽娟2,卢春玲1,常双喜1 1 河南大学附属郑州市第一人民医院呼吸内科郑州450003 2 河南省郑州市中心医院郑州450000 
摘要点击次数: 1022
全文下载次数: 1142
中文摘要:
      目的:探讨苏黄止咳胶囊治疗慢性阻塞性肺病急性加重期的临床疗效。方法:选取2014年9月至2015年9月河南大学附属郑州市第一人民医院收治的老年慢阻肺急性加重期患者90例为研究对象,随机分为观察组和对照组,各45例。对照组患者给予常规治疗,观察组患者在常规治疗的基础上,每天口服苏黄止咳胶囊,1.35 g/次,3次/d,8周为1个疗程。在疗程结束后,进行12个月以上的随访观察。结果:随访期间,观察组与对照组比较,复发次数和复发率明显降低(P<0.01);观察组的FVC、FEV1、FEV1/FVC、MVV均明显升高,RV、RV/TLC均明显降低,与治疗前和对照组比较,差异均有统计学意义(P<0.05);观察组的血清免疫球蛋白IgG、IgA、IgM水平,以及CD3+、CD4+、CD4+/CD8+水平均明显升高,与治疗前和对照组比较,差异均有统计学意义(P<0.05);另外,观察组的生命质量评估表得分明显降低,6 min步行距离明显提高,与治疗前和对照组比较,差异均有统计学意义(P<0.05)。结论:苏黄止咳胶囊口服可以提高慢性阻塞性肺病患者的肺功能,免疫功能,生命质量,减少慢性阻塞性肺病的复发再入院次数和复发率。
English Summary:
      To investigate the long-term follow-up results of Suhuang Zhike capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).Methods:From September 2014 to September 2015,a total of 90 patients with acute exacerbation of COPD in our hospital were randomly divided into treatment group and control group,with 45 cases in each group.The patients in the control group were treated with routine therapy.The patients in the treatment group were treated with Suhuang Zhike capsule in addition to routine therapy,1.35 g / time,3 times a day for 8 weeks.At the end of the course,more than 12 months of follow-up observation was performed.Results:During the follow-up period,the frequency of recurrence and relapse rate of the treatment group were significantly lower than those of the control group (P<0.01).The FVC,FEV1,FEV1 / FVC,MVV of the treatment group were significantly higher and RV and RV / TLC were significantly lower,compared with the control group (P<0.05).In addition,the levels of serum immunoglobulin IgG,IgA,IgM and CD3+,CD4+,CD4+/CD8+ in the treatment group were significantly higher than those of pre-treatment and the control group (P<0.05).Furthermore,the score of the quality of life assessment of the treatment group was significantly reduced,6-min walking distance was significantly increased,compared with those of pre-treatment and the control group,the differences were statistically significant (P<0.05).Conclusion:Suhuang Zhike capsule can improve pulmonary function,immune function and quality of life of patients with COPD and reduce the number of recurrent cases and recurrence rate.
查看全文  查看/发表评论  下载PDF阅读器